ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1622-1628

  Mounier, Nicolas ^a   Brice, P ^b   Bologna, S ^c   Briere, J ^b   Gaillard, I ^d   Heczko, M ^e   Gabarre, J ^f   Casasnovas, O ^g   Jaubert, J ^h   Colin, P ⁱ   Delmer, A ^j   Devidas, A ^k   Bachy, E ^l   Nicolas Virelizier, E ^m   Aoudjhane, A ⁿ   Humbrecht, C ^o   Andre, M ^p   Carde, P ^q   Divine, M ^r   Fenaux, P ^r   Coiffier, B ^r   Reman, O ^r   Aoudjhane, M ^r   Blaise, A M ^r   Bordessoule, D ^r   Bosly, A ^r   Morschhauser, F ^r   Caillot, D ^r   Gonzalez, H ^r   Lederlin, P ^r   Bouabdallah, R ^r   van Hoof, A ^r   Boulat, O ^r   Bauduer, F ^r   Tournilhac, O ^r   Decaudin, D ^r   Sebban, C ^r   Janvier, M ^r   Kentos, A ^r   Voillat, L ^r   Fabbro, M ^r   Eisenmann, J C ^r   Martin, C ^r   Christian, B ^r   Ferrant, A ^r   Salanoubat, C ^r   Varet, B ^r   Bouabdallah, K ^r   de Prijck, B ^r   Levaltier, X ^r   Castaigne, S ^r   Audhuy, B ^r   Frenkiel, N ^r   Rose, C ^r   Fitoussi, O ^r   Orfeuvre, H ^r   Pignon, J M ^r   more..

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Nancy Hospital   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Department of Paediatrics   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h Saint Etienne Hospital   (France)

ⁱ Institut du cancer Courlancy   (France)

^j Department of Urology Andrology   (France)

^k Service d'Endocrinologie et de Diabétologie   (France)

^l CENTRE HOSPITALIER LYON SUD   (France)

^m CENTRE LÉON BÉRARD   (France)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o University of Rouen   (France)

^p Montgodine Hospital   (Belgium)

^q INSTITUT GUSTAVE ROUSSY   (France)

^r NONE

more..

Author keywords

Hodgkin lymphoma; Intensive chemotherapy; Phase 3 trial; Prognostic factors; Secondary malignancy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ALLERGY; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; LOW RISK PATIENT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; THROMBOCYTOPENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; COLITIS; DIGESTIVE SYSTEM DISEASE; INTERNATIONAL PROGNOSTIC SCORE; INTRACARDIAC THROMBOSIS; RISK ASSESSMENT; SCORING SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 84905189678     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu189     Document Type: Article

References (18)

1. Bonadonna G, Viviani S, Bonfante V et al. Survival in Hodgkin's disease patients- report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005; 41: 998-1006.
2. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-3821.
3. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
4. Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-4554.
5. Wongso D, Fuchs M, Plutschow A et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group. J Clin Oncol 2013; 31: 2819-2824.
6. Skoetz N, Trelle S, Rancea M et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943-952.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
8. Moccia AA, Donaldson J, Chhanabhai M et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 2012; 30: 3383-3388.
9. Carde P, Karrasch M, Fortpied C et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles 5> 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): first results of EORTC 20012 Intergroup randomized phase III clinical trial. American Society of Clinical Oncology 48th annual meeting, June, 1-5 2012. J Clin Oncol 2012; 30: Abstr 8002.
10. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
11. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8: 1935-1937.
12. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-811.
13. Viviani S, Zinzani PL, Rambaldi A et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203-212.
14. Borchmann P, Haverkamp H, Diehl V et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234-4242.
15. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-Dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
16. Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PETguided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-1799.
17. Scott DW, Chan FC, Hong F et al. Gene expression-based model using formalinfixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013; 31: 692-700.
18. Younes A, Connors JM, Park SI et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, openlabel, dose-escalation study. Lancet Oncol 2013; 14: 1348-1356.